ATE426174T1 - Verfahren zum nachweis der amyloid-beta oligomere in kírperflussigkeiten - Google Patents

Verfahren zum nachweis der amyloid-beta oligomere in kírperflussigkeiten

Info

Publication number
ATE426174T1
ATE426174T1 AT06118062T AT06118062T ATE426174T1 AT E426174 T1 ATE426174 T1 AT E426174T1 AT 06118062 T AT06118062 T AT 06118062T AT 06118062 T AT06118062 T AT 06118062T AT E426174 T1 ATE426174 T1 AT E426174T1
Authority
AT
Austria
Prior art keywords
body fluids
beta oligomers
oligomers
detecting amyloid
amyloid
Prior art date
Application number
AT06118062T
Other languages
English (en)
Inventor
Santos Alexander Navarrete
Gerald Bihm
Original Assignee
Vista Ventures Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vista Ventures Gmbh filed Critical Vista Ventures Gmbh
Application granted granted Critical
Publication of ATE426174T1 publication Critical patent/ATE426174T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
AT06118062T 2006-07-28 2006-07-28 Verfahren zum nachweis der amyloid-beta oligomere in kírperflussigkeiten ATE426174T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06118062A EP1882944B1 (de) 2006-07-28 2006-07-28 Verfahren zum Nachweis der amyloid-beta Oligomere in Körperflüssigkeiten

Publications (1)

Publication Number Publication Date
ATE426174T1 true ATE426174T1 (de) 2009-04-15

Family

ID=37189402

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06118062T ATE426174T1 (de) 2006-07-28 2006-07-28 Verfahren zum nachweis der amyloid-beta oligomere in kírperflussigkeiten

Country Status (9)

Country Link
US (1) US20100129847A1 (de)
EP (1) EP1882944B1 (de)
JP (1) JP5009987B2 (de)
AT (1) ATE426174T1 (de)
AU (1) AU2007278422A1 (de)
CA (1) CA2693212A1 (de)
DE (1) DE602006005806D1 (de)
ES (1) ES2323725T3 (de)
WO (1) WO2008012101A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
KR20180058863A (ko) 2005-11-30 2018-06-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
EP2586795B1 (de) 2007-10-05 2018-05-16 Genentech, Inc. Verwendung eines Anti-Amyloid-Beta-Antikörpers bei Augenkrankheiten
EP2530464A4 (de) * 2010-01-28 2012-12-05 Panasonic Corp Amyloid-beta-messverfahren
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
EP2415461B1 (de) 2010-07-24 2012-10-31 Roche Diagnostics GmbH Stabilisierung von Interleukin-6 in serumbasierten Lösungen
MY164579A (en) 2010-07-30 2018-01-15 Ac Immune Sa Safe and functional humanized antibodies
EP3533803B1 (de) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antikörper
US9588129B2 (en) 2013-03-15 2017-03-07 Amira Medical Technologies Inc. Methods for analyzing blood to detect diseases associated with abnormal protein aggregation
GB201411616D0 (en) * 2014-06-30 2014-08-13 Cambridge Entpr Ltd Diagnosis and treatment of neurodegenerative disorders
AU2015311836B2 (en) * 2014-09-05 2021-03-11 Presympto, Inc. Methods for detecting amyloid beta oligomers
JP6832283B2 (ja) 2015-09-29 2021-02-24 浜松ホトニクス株式会社 アミロイドβオリゴマーの検出方法、アミロイドβオリゴマー検出装置及びアミロイドβオリゴマー検出プログラム
JP6911026B2 (ja) * 2015-10-30 2021-07-28 ジェネンテック， インコーポレイテッド Ｄ因子活性及びｄ因子阻害剤の力価を測定する方法
US11536731B2 (en) 2017-01-23 2022-12-27 Rensselaer Polytechnic Institute Systems and methods for binding amyloid fibrils using fluorescent protein
CA3139530A1 (en) * 2019-05-10 2020-11-19 Quest Diagnostics Investments Llc Multiplex assay for determining the .beta.-amyloid 42/40 ratio in human plasma specimens
CN117589996A (zh) * 2022-08-09 2024-02-23 深圳智源生物医药有限公司 强毒性淀粉样蛋白寡聚体的诊断用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218506B1 (en) * 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
DE59805338D1 (de) * 1997-09-19 2002-10-02 Evotec Ag Verfahren zur messung der assoziation von teilstrukturen pathologischer proteinablagerungen
US6245572B1 (en) * 1998-05-01 2001-06-12 University Of Tennessee Research Corporation Flow cytometric characterization of amyloid fibrils
DE19952955A1 (de) * 1999-11-03 2001-05-17 Acgt Progenomics Ag Verfahren zur Charakterisierung und zur Auftrennung von molekularen Assoziaten
US20060287337A1 (en) * 2001-11-09 2006-12-21 Proteologics, Inc. Trans-golgi network-associated processes, methods and compositions related thereto
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AU2004272112A1 (en) * 2003-09-12 2005-03-24 The Regents Of The University Of California Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates

Also Published As

Publication number Publication date
ES2323725T3 (es) 2009-07-23
US20100129847A1 (en) 2010-05-27
DE602006005806D1 (de) 2009-04-30
EP1882944A1 (de) 2008-01-30
AU2007278422A1 (en) 2008-01-31
JP5009987B2 (ja) 2012-08-29
JP2009544954A (ja) 2009-12-17
CA2693212A1 (en) 2008-01-31
EP1882944B1 (de) 2009-03-18
WO2008012101A1 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
ATE426174T1 (de) Verfahren zum nachweis der amyloid-beta oligomere in kírperflussigkeiten
DE602004025101D1 (de) Humane anti-humane cd3-bindungsmoleküle
IL225386A (en) Method for diagnosis of cancer by detecting an ereg protein
ATE485517T1 (de) Verfahren zur identifizierung von polypeptid- targets
MA33213B1 (fr) Anticorps antagoniste specifique d'un heterodimere alpha-4-beta-7
UA96139C2 (uk) Антитіло до нейропіліну-1 (nrp1)
ECSP099833A (es) Anticuerpos humanizados contra el globulomero a?(20-42) y sus usos
NO20075671L (no) Neurodegenerative markorer for psykiatriske tilstander
ATE539060T1 (de) Styrylpyridinderivate und ihre verwendung zur bindung und abbildung von amyloider plaque
EA201100231A1 (ru) Диагностический анализ на основе антител
EA201790757A1 (ru) Связывающие антиген cd27l белки
EA200970262A1 (ru) Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам
BRPI0713000A8 (pt) Proteína de ligação multiespecífica de cadeia simples, composição farmacêutica e uso da referida proteína de ligação multiespecífica de cadeia simples
BRPI0415230A (pt) anticorpo biespecìfico de substituição de proteìnas funcionais
DE602007007923D1 (de) Verfahren zur erhöhung der in-vivo-gewinnung therapeutischer polypeptide
ATE476525T1 (de) Verfahren zum nachweis von mit endometrialer krankheit oder phase assoziierten markern
MX353464B (es) Antigenos tpn47 de treponema pallidum, inmunoreactivos, solubles.
AR054479A1 (es) Metodo para diagnosticar l a enfermedad de alzheimer
FI20050176L (fi) Menetelmä kullan talteenottamiseksi sulfidirikasteesta
WO2006042745A3 (de) Chemisch modifizierte iapp - peptidanaloga
EP2486407A4 (de) Verfahren zur diagnose von primärer biliärer cholangitis (pbc) mithilfe neuer autoantigene
EP1860120A4 (de) Verfahren für einen verbesserten antikörper
WO2009025300A1 (ja) イミュノグロブリン結合能を有するペプチド
EA201100253A1 (ru) Глутаминилциклаза в качестве диагностического/прогностического индикатора нейродегенеративных заболеваний
WO2009080017A3 (de) Markersequenzen für neurodegenerative erkrankungen und deren verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties